Barclays Increases Omnicell (NASDAQ:OMCL) Price Target to $58.00

Omnicell (NASDAQ:OMCL) had its price target hoisted by research analysts at Barclays from $39.00 to $58.00 in a research note issued on Thursday, Benzinga reports. The brokerage currently has an “equal weight” rating on the stock. Barclays‘s target price points to a potential upside of 19.17% from the stock’s current price.

OMCL has been the topic of a number of other reports. JPMorgan Chase & Co. raised their price objective on shares of Omnicell from $26.00 to $37.00 and gave the company a “neutral” rating in a report on Friday, August 23rd. Benchmark restated a “buy” rating and issued a $48.00 price objective on shares of Omnicell in a report on Wednesday, October 9th. Craig Hallum raised their price objective on shares of Omnicell from $45.00 to $64.00 and gave the company a “buy” rating in a report on Thursday. StockNews.com upgraded shares of Omnicell from a “hold” rating to a “buy” rating in a report on Saturday, October 19th. Finally, Wells Fargo & Company raised their price objective on shares of Omnicell from $30.00 to $41.00 and gave the company an “equal weight” rating in a report on Monday, October 14th. Five analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to data from MarketBeat, Omnicell presently has an average rating of “Hold” and a consensus target price of $49.14.

Omnicell Stock Performance

Shares of OMCL stock opened at $48.67 on Thursday. The company has a quick ratio of 2.22, a current ratio of 1.05 and a debt-to-equity ratio of 0.47. Omnicell has a 52 week low of $25.12 and a 52 week high of $55.74. The stock has a market capitalization of $2.24 billion, a PE ratio of -124.79, a P/E/G ratio of 58.48 and a beta of 0.83. The firm has a 50 day moving average of $43.34 and a two-hundred day moving average of $35.32.

Omnicell (NASDAQ:OMCL) last issued its quarterly earnings results on Thursday, August 1st. The company reported $0.51 EPS for the quarter, beating the consensus estimate of $0.14 by $0.37. Omnicell had a negative net margin of 1.66% and a positive return on equity of 2.55%. The company had revenue of $276.80 million during the quarter, compared to analysts’ expectations of $254.41 million. During the same quarter last year, the company posted $0.29 EPS. The firm’s revenue was down 7.4% compared to the same quarter last year. On average, research analysts predict that Omnicell will post 0.64 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the business. Arizona State Retirement System increased its stake in Omnicell by 2.9% in the second quarter. Arizona State Retirement System now owns 12,853 shares of the company’s stock valued at $348,000 after purchasing an additional 357 shares during the period. Texas Permanent School Fund Corp boosted its holdings in shares of Omnicell by 1.2% in the first quarter. Texas Permanent School Fund Corp now owns 39,630 shares of the company’s stock valued at $1,158,000 after acquiring an additional 479 shares in the last quarter. Diversified Trust Co boosted its holdings in shares of Omnicell by 3.3% in the second quarter. Diversified Trust Co now owns 15,364 shares of the company’s stock valued at $416,000 after acquiring an additional 494 shares in the last quarter. GAMMA Investing LLC boosted its holdings in shares of Omnicell by 78.4% in the third quarter. GAMMA Investing LLC now owns 1,258 shares of the company’s stock valued at $55,000 after acquiring an additional 553 shares in the last quarter. Finally, Louisiana State Employees Retirement System boosted its holdings in shares of Omnicell by 2.7% in the second quarter. Louisiana State Employees Retirement System now owns 23,100 shares of the company’s stock valued at $625,000 after acquiring an additional 600 shares in the last quarter. 97.70% of the stock is currently owned by institutional investors and hedge funds.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.